6 December 2016
Redx Pharma Plc is pleased to announce that it has presented the pre-clinical profile of its reversible Bruton’s tyrosine kinase (BTK) inhibitor RXC005 at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California, United States, on 5 December 2016.
Redx’s development candidate RXC005 is a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and cysteine-481 (C481) mutated BTK. First generation BTK inhibitors, such as Ibrutinib and Acalabrutinib, specifically target C481 within BTK and mutations at this site interfere with covalent drug binding. Several mutations have been reported and linked to cases of resistance that have emerged in patients with chronic lymphocytic leukaemia (CLL) progression following treatment with Ibrutinib. Redx’s reversible BTK inhibitor RXC005 aims to overcome this resistance mechanism by targeting both wild type and C481-mutated BTK.
The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.
Dr Neil Murray, CEO of Redx, said:
We're delighted to have presented the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the ASH 2016 meeting in San Diego.
RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to Ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017.